These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 24337703)
61. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Sivaprasad U; Abbas T; Dutta A Mol Cancer Ther; 2006 Sep; 5(9):2310-6. PubMed ID: 16985065 [TBL] [Abstract][Full Text] [Related]
62. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096 [TBL] [Abstract][Full Text] [Related]
63. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Kocarek TA; Reddy AB Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853 [TBL] [Abstract][Full Text] [Related]
64. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838 [TBL] [Abstract][Full Text] [Related]
65. Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Robinson AJ; Kashanin D; O'Dowd F; Fitzgerald K; Williams V; Walsh GM Clin Exp Allergy; 2009 Dec; 39(12):1866-74. PubMed ID: 19689459 [TBL] [Abstract][Full Text] [Related]
66. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Ikeda U; Shimpo M; Ohki R; Inaba H; Takahashi M; Yamamoto K; Shimada K Hypertension; 2000 Sep; 36(3):325-9. PubMed ID: 10988259 [TBL] [Abstract][Full Text] [Related]
67. Statins decrease the expression of c-Myc protein in cancer cell lines. Rao PS; Rao US Mol Cell Biochem; 2021 Feb; 476(2):743-755. PubMed ID: 33070276 [TBL] [Abstract][Full Text] [Related]
68. A disconnect between antitumor and antiangiogenic effects of fluvastatin in vitro and in vivo. Klement H; Rak J Neoplasma; 2006; 53(2):111-8. PubMed ID: 16575466 [TBL] [Abstract][Full Text] [Related]
70. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115 [TBL] [Abstract][Full Text] [Related]
71. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129 [TBL] [Abstract][Full Text] [Related]
72. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis. Ikeuchi H; Kuroiwa T; Yamashita S; Hiramatsu N; Maeshima A; Kaneko Y; Hiromura K; Ueki K; Nojima Y Nephron Exp Nephrol; 2004; 97(4):e115-22. PubMed ID: 15331935 [TBL] [Abstract][Full Text] [Related]
73. A review of the lipid-related effects of fluvastatin. Liberopoulos EN; Daskalopoulou SS; Mikhailidis DP; Wierzbicki AS; Elisaf MS Curr Med Res Opin; 2005 Feb; 21(2):231-44. PubMed ID: 15801994 [TBL] [Abstract][Full Text] [Related]
74. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834 [TBL] [Abstract][Full Text] [Related]
75. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890 [TBL] [Abstract][Full Text] [Related]
76. [Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma]. Gao J; Li JS; Xu GL; Jia WD; Ma JL; Yu JH; Ge YS Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):900-4. PubMed ID: 21205474 [TBL] [Abstract][Full Text] [Related]
77. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987 [TBL] [Abstract][Full Text] [Related]
78. Fluvastatin enhances receptor-stimulated intracellular Ca2+ release in human keratinocytes. Coutant KD; Wolff-Winiski B; Ryder NS Biochem Biophys Res Commun; 1998 Apr; 245(2):307-12. PubMed ID: 9571146 [TBL] [Abstract][Full Text] [Related]
79. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Wong WW; Tan MM; Xia Z; Dimitroulakos J; Minden MD; Penn LZ Clin Cancer Res; 2001 Jul; 7(7):2067-75. PubMed ID: 11448925 [TBL] [Abstract][Full Text] [Related]
80. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Jiang P; Mukthavaram R; Chao Y; Nomura N; Bharati IS; Fogal V; Pastorino S; Teng D; Cong X; Pingle SC; Kapoor S; Shetty K; Aggrawal A; Vali S; Abbasi T; Chien S; Kesari S Br J Cancer; 2014 Oct; 111(8):1562-71. PubMed ID: 25093497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]